Seven-year Safety and Efficacy of Somapacitan in Children With GH Deficiency: Final Results From REAL 3

After 7 years of treatment, children with GHD receiving somapacitan experienced consistent increases in height SDS and reduced treatment burden. No new safety concerns were identified.